<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Fernandez-Marcos PJ</submitter><funding>NIAID NIH HHS</funding><pagination>12962-7</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2722271</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>106(31)</volume><pubmed_abstract>Prostate cancer is one of the most common neoplasias in men. The tumor suppressor Par-4 is an important negative regulator of the canonical NF-kappaB pathway and is highly expressed in prostate. Here we show that Par-4 expression is lost in a high percentage of human prostate carcinomas, and this occurs in association with phosphatase and tensin homolog deleted from chromosome 10 (PTEN) loss. Par-4 null mice, similar to PTEN-heterozygous mice, only develop benign prostate lesions, but, importantly, concomitant Par-4 ablation and PTEN-heterozygosity lead to invasive prostate carcinoma in mice. This strong tumorigenic cooperation is anticipated in the preneoplastic prostate epithelium by an additive increase in Akt activation and a synergistic stimulation of NF-kappaB. These results establis</pubmed_abstract><journal>Proceedings of the National Academy of Sciences of the United States of America</journal><pubmed_title>Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF-kappaB activation and invasive prostate carcinoma.</pubmed_title><pmcid>PMC2722271</pmcid><funding_grant_id>R01 AI072581</funding_grant_id><funding_grant_id>R01-AI072581</funding_grant_id><pubmed_authors>Moscat J</pubmed_authors><pubmed_authors>Joshi J</pubmed_authors><pubmed_authors>Castilla EA</pubmed_authors><pubmed_authors>Abu-Baker S</pubmed_authors><pubmed_authors>Saez C</pubmed_authors><pubmed_authors>Collado M</pubmed_authors><pubmed_authors>Palacios J</pubmed_authors><pubmed_authors>Galvez A</pubmed_authors><pubmed_authors>Moreno-Bueno G</pubmed_authors><pubmed_authors>Fernandez-Marcos PJ</pubmed_authors><pubmed_authors>Diaz-Meco MT</pubmed_authors><pubmed_authors>Canamero M</pubmed_authors><pubmed_authors>Leitges M</pubmed_authors><pubmed_authors>Serrano M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF-kappaB activation and invasive prostate carcinoma.</name><description>Prostate cancer is one of the most common neoplasias in men. The tumor suppressor Par-4 is an important negative regulator of the canonical NF-kappaB pathway and is highly expressed in prostate. Here we show that Par-4 expression is lost in a high percentage of human prostate carcinomas, and this occurs in association with phosphatase and tensin homolog deleted from chromosome 10 (PTEN) loss. Par-4 null mice, similar to PTEN-heterozygous mice, only develop benign prostate lesions, but, importantly, concomitant Par-4 ablation and PTEN-heterozygosity lead to invasive prostate carcinoma in mice. This strong tumorigenic cooperation is anticipated in the preneoplastic prostate epithelium by an additive increase in Akt activation and a synergistic stimulation of NF-kappaB. These results establis</description><dates><release>2009-01-01T00:00:00Z</release><publication>2009 Aug</publication><modification>2025-04-05T15:10:10.129Z</modification><creation>2019-03-27T00:24:02Z</creation></dates><accession>S-EPMC2722271</accession><cross_references><pubmed>19470463</pubmed><doi>10.1073/pnas.0813055106</doi></cross_references></HashMap>